Trial Profile
A Pilot Study of Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 19 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 03 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 28 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.